Home » Stocks » IMGN

ImmunoGen, Inc. (IMGN)

Stock Price: $5.45 USD -0.07 (-1.27%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $5.50 +0.05 (0.92%) Nov 30, 6:24 PM

Stock Price Chart

Key Info

Market Cap 1.02B
Revenue (ttm) 91.37M
Net Income (ttm) -70.95M
Shares Out 187.53M
EPS (ttm) -0.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $5.45
Previous Close $5.52
Change ($) -0.07
Change (%) -1.27%
Day's Open 5.49
Day's Range 5.24 - 5.62
Day's Volume 1,662,139
52-Week Range 2.12 - 6.80

More Stats

Market Cap 1.02B
Enterprise Value 858.48M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 187.53M
Float n/a
EPS (basic) -0.40
EPS (diluted) -0.43
FCF / Share -0.67
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 21.23M
Short Ratio 7.49
Short % of Float n/a
Beta 1.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.19
PB Ratio n/a
Revenue 91.37M
Operating Income -50.41M
Net Income -70.95M
Free Cash Flow -116.87M
Net Cash 163.55M
Net Cash / Share 0.87
Gross Margin -35.30%
Operating Margin -55.17%
Profit Margin -77.70%
FCF Margin -127.92%
ROA -12.04%
ROE n/a
ROIC 943.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 5
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(69.72% upside)
Current: $5.45
Target: 9.25
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth53.93%-53.71%92.41%-29.86%42.82%68.55%117.25%-15.27%38.46%-
Gross Profit82.2753.4511560.0085.5459.9035.5416.3619.3113.94
Operating Income-92.17-161-58.98-125-54.46-71.53-73.01-73.26-60.19-51.24
Net Income-104-169-96.01-145-60.74-71.36-72.81-73.32-58.27-50.91
Shares Outstanding14814098.0786.9886.0485.4884.0676.8168.9258.85
Earnings Per Share-0.70-1.21-0.98-1.67-0.71-0.83-0.87-0.95-0.85-0.87
Operating Cash Flow-88.37-1667.65-124-55.29-53.65-60.30-34.29-7.99-40.58
Capital Expenditures-0.53-5.25-1.12-10.38-7.43-8.18-3.77-2.91-2.03-1.53
Free Cash Flow-88.90-1726.53-135-62.72-61.83-64.07-37.20-10.02-42.12
Cash & Equivalents176262267245278142195161192111
Total Debt26.852.062.0596.63------
Net Cash / Debt149260265148278142195161192111
Book Value-76.1210.97-17.90-82.3035.1075.7012283.89140102
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ImmunoGen, Inc.
Country United States
Employees 75
CEO Mark J. Enyedy

Stock Information

Ticker Symbol IMGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IMGN
IPO Date November 16, 1989


ImmunoGen, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.